BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:14 PM
 | 
May 25, 2010
 |  BC Extra  |  Clinical News

Teva begins trial for anti-CD20 biologic

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) began a Phase I/II trial in rheumatoid arthritis (RA) evaluating TL011, an anti- CD20 biologic, vs. MabThera rituximab, a chimeric...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >